0001209191-23-025128.txt : 20230421
0001209191-23-025128.hdr.sgml : 20230421
20230421160535
ACCESSION NUMBER: 0001209191-23-025128
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230419
FILED AS OF DATE: 20230421
DATE AS OF CHANGE: 20230421
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sinha Vikas
CENTRAL INDEX KEY: 0001337845
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39409
FILM NUMBER: 23836347
MAIL ADDRESS:
STREET 1: C/O ALEXION PHARMACUETICALS, INC.
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allovir, Inc.
CENTRAL INDEX KEY: 0001754068
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 831971007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (617) 433-2605
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: ViraCyte, Inc.
DATE OF NAME CHANGE: 20180924
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-19
0
0001754068
Allovir, Inc.
ALVR
0001337845
Sinha Vikas
C/O ALLOVIR, INC.
1100 WINTER STREET
WALTHAM
MA
02451
1
1
1
0
See Remarks
1
Common Stock
2023-04-19
4
S
0
1217
3.7087
D
1186521
D
Common Stock
2023-04-20
4
S
0
1466
3.6255
D
1185055
D
Common Stock
16674766
I
Shares held by ElevateBio LLC
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.64 to $3.84.
Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.62 to $3.64.
Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared
voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to
the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial
ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Officer Title: President and Chief Financial Officer
/s/ Brett Hagen, as Attorney-in-Fact
2023-04-21